SAR 411298Alternative Names: SAR411298
Latest Information Update: 02 May 2012
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Mechanism of Action Fatty acid amide hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer pain
Most Recent Events
- 31 Mar 2012 Discontinued - Phase-I for Cancer pain in Europe (unspecified route)
- 09 Feb 2011 Phase-I clinical trials in Cancer pain in Europe (unspecified route)